Who We Are

Orchidia Pharmaceutical Industries (Orchidia) is an outstanding Egyptian company specialized in the production of pharmaceutical ophthalmic products, ranked number two in the Egyptian ophthalmic market with the highest growth rate in this market. Orchidia has its own manufacturing facility in Al-Obour city on 6,000 M² Footprint and considered one of the biggest in the Middle East region with a current production capacity of 35 million units. 

Orchidia certified with WHO-GMP implementation from Egyptian MOH and other countries of registration in the Middle East and Africa, ISO 9001, ISO 14001 and OHSAS. We maintain and continually improve our Quality Management Systems (QMS) and Environmental Health and Safety (EHS) to achieve the required quality level and exceeding expectations of our stakeholders. 

Our current portfolio includes 35 ophthalmic drugs, and 3 medical devices obtain the CE marked certificates. In addition to a rich pipeline of 60 drugs in different ophthalmic drug forms. Our CE products are registered in Germany; our authorized representative there is MDSS( Medical Device Safety Services.

Orchidia products are available outside our national borders in 17 countries, mainly in MEA region. The company is in the process of registration in several countries.

Orchidia currently poses three eye drops filling production lines; two Rommelag machines are working with the Blow Fill Seal Technology (BFS) without any human intervention through the whole sterile operation, and the other filling machine, CAM Sterile Filling Machine, is a conventional sterile filling line supported with bottles Capping machine. 
The complete drops filling process is performed in a sterile area which is under intensive sterilization, validation, and qualification in a strict time plan. 

In 2017, we have received and installed a new filling machine for single dose units (SDU) with BFS technology. New single dose, preservative free, ophthalmic products, this machine is considered as a strategic expansion for our market share. The company will introduce with a new single dose preservative-free ophthalmic products to start skimming in the single dose products market by Q1 of 2018, with a very promising forecasted sales plan for the next 5 years.
 
Orchidia is producing different forms of ophthalmic drugs including eye drops, contact lenses solutions, gel, suspension and furthermore single dose, preservative free, products in 2018.The company will introduce ointments, prefilled syringes, and multi-dose preservative free within the next three years.